The Recall Desk
SevereFDA (Drugs)·D-832-2013·Announced 2013-08-14

Sandoz Recalls Methotrexate Injection Vials Due to Particulate Matter

Sandoz Incorporated is recalling specific lots of Methotrexate Injection vials because particulate matter was found in retention samples.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 according to the rubric.

Plain-English summary

Sandoz Incorporated is recalling 1,635 vials of Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL Single Dose Vial. The recall involves products with NDC 66758-041-01, manufactured for Sandoz Inc. in Princeton, NJ, and manufactured by EBEWE Pharma Ges.m.b.H. Nfg.KG in Austria.

The recall was initiated because particulate matter was found during the examination of retention samples. The affected lots are CL0996 (Expiration 12/13) and CJ4948 (Expiration 05/13). The products were distributed nationwide.

Healthcare providers and patients should stop using the affected vials and contact Sandoz Incorporated for further instructions or to arrange for a return.

The recalled product

Product
Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL Single Dose Vial, Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540; Manufactured by: EBEWE Pharma Ges.m.b.H. Nfg.KG, A-4866 Unterach, AUSTRIA, NDC 66758-041-01.
Affected units
1,635

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot #: CL0996
  • Exp 12/13
  • and CJ4948
  • Exp 05/13

Distribution

Distributed nationwide across the United States.